Abstract
This chapter describes the pharmacological and clinical characteristics of four botulinum toxins- Botox, Xeomin, Dysport and Myobloc- currently approved by FDA for use in the US. Two other unapproved but widely used botulinum toxins in Asia, Prosigne and Meditox are also briefly discussed. In addition, the structure of clinical trials and definition of study phases, I, II, III, IV as pertains to clinical investigations are provided. The classification of clinical studies based on their quality- class I to IV and their level of study efficacy- A, B, C, U - are described using the guidelines provided by the Assessment and Therapeutics Subcommittee of the American Academy of Neurology.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Chen JJ, Dashtipour K. Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer. Pharmacotherapy. 2013;33:304–18.
Brin MF, Comella CL, Jankovic J, Lai F, Naumann M. CD-017 BoNTA study group. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008;23:1353–60.
Dressler D. Five-year experience with incobotulinumtoxinA (Xeomin(®) ): the first botulinum toxin drug free of complexing proteins. Eur J Neurol. 2012;19:385–9.
Dressler D, Bigalke H. Long-term stability of reconstituted incobotulinumtoxinA: how can we reduce costs of botulinum toxin therapy? J Neural Transm (Vienna). 2017 Aug 2; https://doi.org/10.1007/s00702-017-1767-y. [Epub ahead of print]
Lorenc ZP, Kenkel JM, Fagien S, et al. A review of AbobotulinumtoxinA (Dysport). Aesthet Surg J. 2013;33(1 Suppl):13S–7S.
Lew MF, Chinnapongse R, Zhang Y, Corliss M. RimabotulinumtoxinB effects on pain associated with cervical dystonia: results of placebo and comparator-controlled studies. Int J Neurosci. 2010;120:298–300.
Kaji R, Shimizu H, Takase T, Osawa M, Yanagisawa N. A double-blind comparative study to evaluate the efficacy and safety of NerBloc® (rimabotulinumtoxinB) administered in a single dose to patients with cervical dystonia. Brain Nerve. 2013;65:203–11.
Quagliato EM, Carelli EF, Viana MA. A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia. Clin Neuropharmacol. 2010;33:22–6.
Rieder CR, Schestatsky P, Socal MP, et al. A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm. Clin Neuropharmacol. 2007;30:39–42.
French J, Gronseth G. Lost in a jungle of evidence: we need a compass. Neurology. 2008;71:1634–8.
Gronseth G, French J. Practice parameters and technology assessments: what they are, what they are not, and why you should care. Neurology. 2008;71:1639–43.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Jabbari, B. (2018). Botox and Other Neurotoxins. In: Botulinum Toxin Treatment . Springer, Cham. https://doi.org/10.1007/978-3-319-99945-6_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-99945-6_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-99944-9
Online ISBN: 978-3-319-99945-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)